Arsenic Trioxide During Consolidation for Patients with Previously Untreated Low/Intermediate Risk Acute Promyelocytic Leukaemia May Eliminate the Need for Maintenance Therapy

A total of 105 patients (age ≥ 18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic trioxide (ATO). Sixty-eight patients who were polymerase chain reaction (PCR) negative for PML...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Coutre, Steven E., Othus, Megan, Powell, Bayard, Willman, Cheryl L., Stock, Wendy, Paietta, Elisabeth, Levitan, Denise, Wetzler, Meir, Attar, Eyal C., Altman, Jessica K., Gore, Steven D., Maher, Tracy, Kopecky, Kenneth J., Tallman, Martin S., Larson, Richard A., Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064464/
https://ncbi.nlm.nih.gov/pubmed/24528179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12775
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados